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Study period:
• September 2016 through September 2019
Data collection:
• Electronic health record-based retrospective cohort
Study population:
• Patients >18 years old undergoing PCI with drug-eluting stent 
placement 
• Patients prescribed DAPT – consisting of clopidogrel, 
ticagrelor, or prasugrel – upon discharge
• Patients presenting with acute coronary syndrome
Exclusion criteria:
• Past and/or current diagnosis of cancer
• Pregnancy
• To ensure appropriate length of follow-up, patients were also 
excluded if they did not have a documented chart encounter 
after 30 days of the index PCI
Outcomes measured:
• MACE, defined as myocardial infarction (MI) or ischemic stroke 
(IS)
• Other ischemic events, defined as stent thrombosis (ST) or 
unstable angina (UA)
From September 2016 through September 2019, overall P2Y12 inhibitor 
prescribing rates compared favorably to the optimal prescribing rates 
noted in the primary objective. Ticagrelor or prasugrel were prescribed at 
an overall rate of 26.9%, while clopidogrel was prescribed at a rate of 
73.1%. Additionally, prescribing of ticagrelor has increased over time, 
being possibly influenced by ACC/AHA and ESC guideline updates. 
Prescribing habits showed that ticagrelor is more likely to be prescribed 
with an index diagnosis of STEMI, compared to NSTEMI or unstable 
angina. Within the past year, the POPular Genetics trial suggests that a 
genotype-guided strategy, with 61% of patients receiving clopidogrel, 
was non-inferior to those receiving ticagrelor in patients diagnosed with 
STEMI and undergoing PCI.5 The genotype-guided arm also 
experienced significantly fewer minor bleeding events. Thus, CYP2C19 
screening may help support prescriber decision-making in consideration 
of the index diagnosis. 
Event rates among both groups are more pronounced within the initial 
30 days post-index PCI, with 26% of total initial readmissions occurring 
during this period. These rates highlight the necessity of early, targeted 
P2Y12 inhibitor prescribing. Additionally, individuals receiving clopidogrel 
showed a significantly higher incidence of MACE plus other ischemic 
events (p=0.01) occurring after 1 year. Cumulative failure rates for the 
clopidogrel group were also comparatively higher throughout the entirety 
of this period. 
A potential explanation for the increased event rates in the clopidogrel 
group is individuals, with one or more loss of function alleles, are being 
sub-optimally prescribed clopidogrel. A genotype-guided strategy could 
help mitigate these risks by allowing for targeted P2Y12 inhibitor 
prescribing, resulting in improved clinical outcomes. 
A simulated analysis was completed utilizing incidence rates associated 
with a genotype-guided strategy,4 and also utilizing prescribing 
frequencies demonstrated by this study. The rate of MACE and other 
ischemic events was reduced by 57% in the simulated cohort. This 
reduction equated to savings of $527,377, or $1,325 per person, with 
savings attributed to reduced readmissions due to adverse outcomes. 
Limitations of this retrospective cohort study include the potential for 
missed events not documented within the electronic medical record and 
the inability to control for other confounding factors. There was also 
notable attrition within the ticagrelor group, with 45 patients 
discontinuing therapy after a median of 37 days. Discontinuation of 
ticagrelor was most commonly associated with cost and dyspnea, at 
49% and 29%, respectively. However, this high rate of discontinuation 
supports the utilization of a genotype-guided strategy in matching 
patients with the most optimal agent in regards to tolerability and cost. 
Lastly, CYP2C19 status is not the only contributor associated with a 
poor response to clopidogrel, and this study did not assess other factors 
contributing towards platelet reactivity. 
The emergence of pharmacogenomics offers the opportunity to practice 
precision medicine across healthcare, including within patients 
presenting with acute coronary syndrome (ACS).
In patients presenting with ACS and undergoing percutaneous coronary 
intervention (PCI) with stent placement, dual antiplatelet therapy (DAPT) 
is routinely prescribed for a minimum of 12 months post-PCI1. DAPT 
consists of a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) plus 
aspirin.
The American College of Cardiology (ACC), the American Heart 
Association (AHA), and the European Society of Cardiology (ESC) favor 
ticagrelor or prasugrel over clopidogrel in patients diagnosed with ACS 
who receive DAPT post-PCI.1 These guidelines do not recommend for 
routine genetic testing. Comparatively, the Clinical Pharmacogenetics 
Implementation Consortium provides guidance on tailored P2Y12 
inhibitor therapy dependent on CYP2C19 status, with ticagrelor or 
prasugrel being favored in poor or intermediate metabolizers.2
Consequently, selection of a P2Y12 inhibitor may be influenced by both 
prescribing practices and patient-specific factors. 
Approximately 30% of the North American population carry at least one 
CYP2C19 allele associated with reduced metabolism of clopidogrel, 
potentially increasing their risk for adverse outcomes and treatment 
failure.3 Ticagrelor and prasugrel are not impacted by CYP2C19 
metabolism, but are associated with increased bleeding risk and cost.
The utilization of CYP2C19 genetic testing could optimize P2Y12 
inhibitor prescribing, potentially resulting in improved clinical outcomes 
and cost savings. Recent studies have provided increasingly positive 
evidence that a genotype-guided strategy for DAPT results in reduced 
adverse events.4,5 Additionally, future guideline recommendations may 
be impacted by these studies. This retrospective cohort analysis aims to 
identify how CYP2C19 genetic testing may impact clinical practice within 
an inpatient setting. 
Figure 1. Prescribing Rates Over Time
Purpose
To evaluate the potential utility of CYP2C19 genetic testing for patients 
presenting with ACS and receiving DAPT after undergoing PCI within 
two large, tertiary medical centers 
Methodology
Primary
• Evaluate the incidence of optimal P2Y12 inhibitor prescribing in a 
retrospective cohort
o Defined as those projected to have at least one loss of function allele being 
prescribed ticagrelor or prasugrel (30%), and those projected without a loss of 
function allele being prescribed clopidogrel (70%)
Secondary
• Evaluate readmissions associated with major cardiovascular 
adverse events (MACE) at 30 days and 1 year
• Evaluate readmissions associated with stent thrombosis at 30 
days and 1 year
• Perform a cost analysis between the study cohort and a 
simulated cohort utilizing a genotype-guided strategy at 1 year
Results
Figure 4. Initial Readmission Events Over 1 Year
Figure 2. Prescribing Rates Per Index Diagnosis
Figure 6. Cost-analysis Among Cohorts
Health & Services
Study Cohort (N=398)
P2Y12 Inhibitor 
(Rx) 
Clopidogrel Ticagrelor
Cost of 1 year
supply‡ per 
person
$60 $4,624
Prescribing 
frequency
0.73 0.26
Total Cost of Rx $495,924
CYP2C19 Test† N/A
Total Cost of Rx 
plus Test
$495,924
Total Event 
Incidence
15.3%
Total Events 61
Total Aggregate 
Cost of Events◊
$1,120,997
Total Cost of Rx 
Plus Test Plus 
Events
$1,616,921
Simulated Cohort (N=398)
P2Y12 Inhibitor 
(Rx)
Clopidogrel Ticagrelor
Cost of 1 year
supply‡ per 
person
$60 $4,624 
Prescribing 
frequency
0.73 0.26
Total Cost of Rx $495,924
CYP2C19 Test† $115,818
Total Cost of Rx 
plus Test
$684,640 
Total Event 
Incidence4
6.6%
Total Events 26
Total Aggregate 
Cost of Events◊
$477,802
Total Cost of Rx
Plus Test Plus 
Events
$1,089,544
Figure 3. Initial Readmission Events Over 30 Days
Note: Prescribing rates were not found to be significantly different between NSTEMI 
vs. UA (p=0.71). However, prescribing rates were found to be significantly different 
between NSTEMI vs. STEMI (p=0.00) and UA vs. STEMI (p=0.00)
Table 2. Evaluation of Genotype-guided DAPT over 1 year
Note: Statistically significant differences (p=0.01) were found between “MACE plus 
other” rates between the clopidogrel and ticagrelor groups 
Table 1. Event Rates Over 30 Days and 1 Year Figure 5. Cumulative Failure Rates Over Time
This retrospective cohort study at two large, tertiary medical centers 
demonstrated that overall P2Y12 inhibitor prescribing rates compared 
favorably to the expected distribution of CYP2C19 phenotypes among 
the North American population, with a trend towards increased 
prescribing of ticagrelor. However, significantly increased MACE plus 
other ischemic events over 1 year in the clopidogrel group demonstrate 
that P2Y12 inhibitor prescribing can be optimized utilizing a genotype-
guided strategy. 
As event rates were higher within the initial 30 day period post-PCI, 
initiating CYP2C19 genetic screening promptly and during inpatient 
admission may help minimize early readmission. CYP2C19 genetic 
screening may also help guide optimal prescribing practices in 
consideration of other factors, such as the tolerability of the medication 
regimen. Lastly, a genotype-guided strategy may reduce costs for both 
the health system and the patient. 
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